clinical trial
Search documents
Could digital twins – virtual replicas of humans or organs – accelerate medical research? 🏥
Google DeepMind· 2025-07-03 11:17
Digital Twins in Healthcare - Digital twins are a significant topic, especially for healthcare applications [1] - The concept involves creating digital replicas for individual healthcare purposes, with varied interpretations [1] Pharmaceutical Industry Applications - The pharma industry explores digital twins to enhance clinical trials [2] - Virtual cohorts could potentially reduce the number of participants needed in clinical trials while maintaining knowledge about drug safety and efficacy [2][3] - This approach simulates human systems (e g, organs) to minimize reliance on human subjects in trials [2]
2 Beaten-Down Stocks With Massive Upside Potential
The Motley Fool· 2025-07-03 11:00
Group 1: CRISPR Therapeutics - CRISPR Therapeutics has developed Casgevy, the first gene-editing medicine approved using the CRISPR technique, but the stock has been on a downward trend since 2021 due to clinical progress, complexity of therapy administration, and unprofitability [3][4] - The company is targeting challenging areas such as type 1 diabetes and hard-to-treat cancers, with expected data readouts for ongoing clinical trials as early as this year, which could positively impact stock performance [5] - Casgevy has significant financial implications, with a treatment cost of $2.2 million in the U.S. and an estimated 60,000 patients in target geographies, indicating blockbuster potential [9] Group 2: Viking Therapeutics - Viking Therapeutics gained attention after strong phase 2 results for VK2735, an investigational weight management therapy, but has seen stock performance decline as investors took profits [10] - The anti-obesity therapy market is rapidly growing, and Viking's VK2735 has shown promising mid-stage data, with an oral formulation currently in Phase 2 studies [11] - Viking Therapeutics has a robust pipeline, including VK2809 for metabolic dysfunction-associated steatohepatitis entering phase 3 studies and VK0214 for X-linked adrenoleukodystrophy, which has received orphan drug designation [12][13]
高盛：全球医疗保-2025 年第三季度值得关注的生物制药催化因素
Goldman Sachs· 2025-07-03 02:41
Global Healthcare Biopharma catalysts to watch in 3Q25 With macroeconomic volatility and healthcare policy uncertainty persisting likely into the back half of the year, we continue to advocate for and highlight idiosyncratic catalysts with attractive risk/reward setups to drive alpha generation. Herein, we highlight and preview key catalysts in 3Q25 across the GS biotechnology coverage universe from pivotal studies: BMY's Cobenfy ADEPT-2 in Alzheimer's disease psychosis; LLY's orforglipron ATTAIN-1 in obesi ...
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
Globenewswire· 2025-06-26 12:00
Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical t ...
